Our lead antibody candidate, XmAb®2513, completed a Phase 1 clinical trial for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. XmAb®2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been engineered to contain an XmAb® Fc domain to greatly increase its cytotoxic potency (ADCC). XmAb®2513 shows superior activity in recruiting primary human immune cells to kill tumor cells in in vitro models and is active in blocking tumor growth in rodent models. The compound was also humanized with Xencor’s XmAb® Fv technology. In data presented at the 2009 ASCO Annual Meeting, objective tumor responses were observed and XmAb®2513 was generally well tolerated. XmAb®2513 is readily manufactured using standard monoclonal antibody production methods.
About Hodgkin’s Lymphoma
According to the U.S. National Institutes of Health, lymphomas account for about five percent of all cases of cancer in the U.S. Of the nearly 500,000 Americans with lymphoma, 142,000 are cases in Hodgkin’s lymphoma (HL), according to the Lymphoma Research Foundation (LRF). HL is most often treated with a chemotherapy regimen, radiation therapy or a combination of the two. Early stage HL, in particular, has a cure rate of approximately 93%; however, 10-20% of patients with advanced-stage HL will die after relapse or progressive disease. Standard of care combined cytotoxic chemotherapy and radiation therapy, although curative in the majority of early-stage patients, results in significant long-term morbidity. Secondary malignant conditions and cardiovascular events are reported to each have a cumulative occurrence of approximately 25-30% at 30 years after therapy.